MCO Pharmacy Directors Favor Individual, Generic Drugs Versus Newer Single-Pill Fixed Combination Brands, According to a New Report from HealthLeaders-InterStudy
NASHVILLE, Tenn., Dec. 10 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, finds that although Novartis' Exforge and Tekturna have slowly penetrated tier 2 levels of managed care organization (MCO) formularies over the last 12 months, their progress has stalled. Tekturna has stumbled from having 5.1 percent of U.S. patients accessing the drug at tier 2 in August 2008 to having only 3.9 percent of all patients with access at that same level in November 2008. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations, more surveyed MCO pharmacy directors indicate that they have downgraded Exforge's and Tekturna's tier position and/or added step therapy restrictions than indicated they had improved tier positioning of the drugs.
"The future reimbursement outlook for repackaging of individual hypertension agents is not that promising," according to Jason Labonte, Ph.D., vice president at HealthLeaders-InterStudy. "Forty-four to 67 percent of survey respondents favor use of individual (and often generic) drugs versus the newer single-pill, fixed-combination brands like Exforge and Daiichi Sankyo's Azor."
About Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations
The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level MCOs. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows users to cut-and-paste graphs and data into their own presentations.
About Formulary Forum
Formulary Forum is the first and only source for identifying the trends in formulary positioning of competing agents, understanding why those trends were taking place and predicting what changes lay ahead for brand positioning in the face of both patent expiries and new drug launches. The new report series from HealthLeaders-InterStudy combines historical formulary data from Fingertip Formulary, which maintains the highest quality and most comprehensive, integrated database of formulary information in the United States, with a robust survey of 50 MCO pharmacy directors. The pharmacy directors responses reveal what events triggered movement of key brands within their formulary for a specific disease as well as what moves they expect to make in formulary structure as new brands enter the market.
About Fingertip Formulary
Fingertip Formulary (www.FingertipFormulary.com) offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others, in the United States. Fingertip Formulary is a Decision Resources, Inc. company.
HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Lisa Osgood Elizabeth Marshall HealthLeaders-InterStudy Decision Resources, Inc. 781-296-2606 781-296-2563 email@example.com firstname.lastname@example.org
Copyright©2008 PR Newswire.
All rights reserved